ClinicalTrials.gg
TerminatedNCT00773383Updated Jun 24, 2013Results posted

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.

A Phase 2 interventional study of RG1507 and erlotinib [Tarceva] in Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche. Terminated at 16 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-06-24.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche — 5 open to participants now, 16 under way, 8 of them phase 3. Carcinoma, Non-Small-Cell Lung · Hoffmann-La Roche.

Enrollment
117th of 142
35 · median 136
Started
2008
with 8 others
Phase 2
56 of 182
none open now
Registered
27th of 182
by date

Among the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, this one is the 117th largest by enrollment of the 142 interventional ones that give a count, is one of 9 that started in 2008, is one of 56 in phase 2, and was the 27th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This single arm study in patients with advanced Stage IIIb/IV NSCLC who have progressive disease after deriving clinical benefit (defined as response or stable disease after 12 weeks) from second or third line Tarceva monotherapy will determine the proportion of patients with progression-free survival at 12 weeks following combination therapy with R1507 and Tarceva. Patients will receive R1507 (9mg/kg iv) weekly in combination with Tarceva (150mg oral daily) for up to a maximum of 24 months. Other disease-related endpoints including overall survival, objective response rate, time to response, time to progressive disease and duration of response will also be evaluated. The anticipated time on study treatment is 1-2 years, and the target sample size is \<100 individuals.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female patients >=18 years with documented inoperable, locally advanced or (stage IIIB or IV) NSCLC;
  • currently receiving Tarceva monotherapy and having failed at least one standard chemotherapy regimens;
  • prior response or stable disease 12 weeks from start of Tarceva;
  • documented progressive disease at enrollment;
  • according to the criteria;
  • performance status 0-2;
  • >12 weeks.

Exclusion criteria

Exclusion Criteria:

  • patients with active CNS lesions;
  • prior treatment with agents acting via IGF-1R inhibition or EGFR targeting;
  • administration with high doses of systemic ;
  • radiotherapy in the 4 weeks prior to study start;
  • surgery or significant traumatic injury with in the last 2 weeks prior to study start.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    1

    Drug: RG1507 · Drug: erlotinib [Tarceva]

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Progression Free Survival (PFS)

    The primary efficacy endpoint is progression-free survival at 12 weeks after start of therapy. A progression-free survival rate at 12 weeks will be calculated, with patients categorized in a dichotomous manner as alive and progression-free or in progression or dead at 12 weeks.

    Time frame: 12 weeks

Secondary outcomes

  1. Duration of Overall Survival

    The study was prematurely terminated due to discontinuation of R1507 development (not for safety reasons). As a result, data not provided for outcome measures listed.

    Time frame: From start of treatment to death; up to the time that all participants ended treatment

  2. Participants Achieving Objective Response

    Objective response is defined as a complete response (CR) or partial response (PR) that has been confirmed by a second tumor assessment no earlier than 4 weeks after the initial documentation. Response is assessed using Response Evaluation Criteria in Solid Tumors (RECIST)criteria. The study was prematurely terminated due to discontinuation of R1507 development (not for safety reasons). As a result, data not provided for outcome measures listed.

    Time frame: Patients were followed from start of therapy until date of first response

  3. Time to Best Response

    This is defined as time from the start of therapy to the date of first CR or PR. The study was prematurely terminated due to discontinuation of R1507 development (not for safety reasons). As a result, data not provided for outcome measures listed.

    Time frame: Patients were followed from start of therapy until date of first response

  4. Time to Progressive Disease (PD)

    The study was prematurely terminated due to discontinuation of R1507 development (not for safety reasons). As a result, data not provided for outcome measures listed.

    Time frame: From start of therapy to the date of first documentation of PD. Pts who never progress prior to final analysis or are withdrawn from the study without documented progression will be censored at the date of the last valid tumor assessment.

  5. Duration of Objective Response

    This is defined similarly for complete and partial responders. Complete response or partial response lasts from the date the complete response or partial response was first recorded to the date on which progressive disease is first noted or date of death. If a patient does not progress or die while being followed, the date of the last valid tumor assessment will be taken. The study was prematurely terminated due to discontinuation of R1507 development (not for safety reasons). As a result, data not provided for outcome measures listed.

    Time frame: from the date the complete or partial response was first recorded to the date which progressive disease is first noted or date of death. If a patient does not progress or die while being followed, the date of the last valid tumor assessment will be taken

  6. Baseline Electrocardiogram (ECG)

    Standard safety monitoring includes baseline Electrocardiogram (ECG). The study was prematurely terminated due to discontinuation of R1507 development (not for safety reasons). As a result, data not provided for outcome measures listed. The study was prematurely terminated due to discontinuation of R1507 development (not for safety reasons). As a result, data not provided for outcome measures listed.

    Time frame: baseline within 28 days of starting treatment (screening visit).

  7. Fasting Glucose, Highest Post-Baseline Value

    A fasting glucose was required at baseline, and random non-fasting glucose testing was performed weekly for the first 6 weeks followed by day 1 of each 3 week treatment phase. The number of participants with the highest post-baseline fasting glucose level at any time point post baseline relative to the participant's baseline glucose level is reported.

    Time frame: Baseline, Highest Post-Baseline value within the timeframe of post-baseline collection up to when patient discontinued (up to 59 weeks)

  8. Hemoglobin A1c (HbA1c)

    Standard safety monitoring includes baseline Electrocardiogram (ECG), Fasting glucose and HbA1c, monthly urine pregnancy test in female patients of childbearing potential and Human anti-human antibody (HAHA) testing. Data will be represented in the Serious Adverse Event (SAE) Adverse Event (AE) section of Protocol Registration System (PRS).

    Time frame: screening

  9. Monthly Urine Pregnancy Test in Female Patients of Childbearing Potential

    Standard safety monitoring includes baseline Electrocardiogram (ECG), Fasting glucose and HbA1c, monthly urine pregnancy test in female patients of childbearing potential and Human anti-human antibody (HAHA) testing. Not posted; it will be represented in the Serious Adverse Event (SAE) Adverse Event (AE) section of Protocol Registration System (PRS).

    Time frame: Within 7 days of starting treatment (baseline visit)

  10. Number of Participants With Positive Results for Human Anti-human Antibody (HAHA) Testing

    Number of participants who tested positive for Human anti-human antibody (HAHA) testing for immunogenicity. To determine HAHA specificity, screened positive samples were tested in a confirmatory assay in the presence of 10 ug/mL R1507. Samples with \> 19.7% inhibition were considered true positives, whereas those with \< 19.7% inhibition were considered to be false positives.

    Time frame: prior to dosing on week 1 (day 1), week 4 (day 22), week 10 (day 64), final visit, follow up visit and 12 weeks post last dose (up to 71 weeks)

  11. Electrocardiogram (ECG)

    12 lead ECG is required at baseline and will be measured during the trial as clinically indicated at the discretion of the investigators. For each reading, QTcF value will be calculated as the QT value (seconds) divided by the cube root of the RR interval in seconds (Fridericia correction). A listing will be generated showing, for each patient, the visits at which ECGs were taken and the results (normal or abnormal, as well as any comments provided).

    Time frame: baseline and thereafter as clinically indicated at the discretion of the investigator up to the time that the patient discontinued (up to 59 weeks)

  12. Population Pharmacokinetics of R1507 and Tarceva

    Population PK of R1507 and erlotinib were planned but not analyzed due to the termination of the trial.

    Time frame: Throughout study

  13. Assessment of Potential Predictive and Prognostic Biomarkers.

    Total IGF-I, free IGF I/II and other potential biomarkers present in serum. Further putative biomarker analyses in blood and tumor samples were planned in the protocol for exploratory assessment of correlation with clinical outcome. None of these were analyzed due to the termination of the trial.

    Time frame: Throughout study

07

Results

Posted Sep 16, 2011

Participant flow

Participant flow — Overall Study
MilestoneR1507
Started35
Received study drug34
Completed4
Not completed31
Withdrew: Adverse event4
Withdrew: Death1
Withdrew: Progression of disease23
Withdrew: Other2
Withdrew: No study dose received1

Outcome measures

PrimaryPercentage of Participants With Progression Free Survival (PFS)

The primary efficacy endpoint is progression-free survival at 12 weeks after start of therapy. A progression-free survival rate at 12 weeks will be calculated, with patients categorized in a dichotomous manner as alive and progression-free or in progression or dead at 12 weeks.

Time frame:
12 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Progression Free Survival (PFS)
Percentage of participantsR1507
Progression-Free & Alive32.4 (17.4 to 50.5)
Progressed, Died, or Unknown67.6 (0 to 0)
SecondaryDuration of Overall Survival

The study was prematurely terminated due to discontinuation of R1507 development (not for safety reasons). As a result, data not provided for outcome measures listed.

Time frame:
From start of treatment to death; up to the time that all participants ended treatment

No measurements were reported for this outcome.

SecondaryParticipants Achieving Objective Response

Objective response is defined as a complete response (CR) or partial response (PR) that has been confirmed by a second tumor assessment no earlier than 4 weeks after the initial documentation. Response is assessed using Response Evaluation Criteria in Solid Tumors (RECIST)criteria. The study was prematurely terminated due to discontinuation of R1507 development (not for safety reasons). As a result, data not provided for outcome measures listed.

Time frame:
Patients were followed from start of therapy until date of first response

No measurements were reported for this outcome.

SecondaryTime to Best Response

This is defined as time from the start of therapy to the date of first CR or PR. The study was prematurely terminated due to discontinuation of R1507 development (not for safety reasons). As a result, data not provided for outcome measures listed.

Time frame:
Patients were followed from start of therapy until date of first response

No measurements were reported for this outcome.

SecondaryTime to Progressive Disease (PD)

The study was prematurely terminated due to discontinuation of R1507 development (not for safety reasons). As a result, data not provided for outcome measures listed.

Time frame:
From start of therapy to the date of first documentation of PD. Pts who never progress prior to final analysis or are withdrawn from the study without documented progression will be censored at the date of the last valid tumor assessment.

No measurements were reported for this outcome.

SecondaryDuration of Objective Response

This is defined similarly for complete and partial responders. Complete response or partial response lasts from the date the complete response or partial response was first recorded to the date on which progressive disease is first noted or date of death. If a patient does not progress or die while being followed, the date of the last valid tumor assessment will be taken. The study was prematurely terminated due to discontinuation of R1507 development (not for safety reasons). As a result, data not provided for outcome measures listed.

Time frame:
from the date the complete or partial response was first recorded to the date which progressive disease is first noted or date of death. If a patient does not progress or die while being followed, the date of the last valid tumor assessment will be taken

No measurements were reported for this outcome.

SecondaryBaseline Electrocardiogram (ECG)

Standard safety monitoring includes baseline Electrocardiogram (ECG). The study was prematurely terminated due to discontinuation of R1507 development (not for safety reasons). As a result, data not provided for outcome measures listed. The study was prematurely terminated due to discontinuation of R1507 development (not for safety reasons). As a result, data not provided for outcome measures listed.

Time frame:
baseline within 28 days of starting treatment (screening visit).

No measurements were reported for this outcome.

SecondaryFasting Glucose, Highest Post-Baseline Value

A fasting glucose was required at baseline, and random non-fasting glucose testing was performed weekly for the first 6 weeks followed by day 1 of each 3 week treatment phase. The number of participants with the highest post-baseline fasting glucose level at any time point post baseline relative to the participant's baseline glucose level is reported.

Time frame:
Baseline, Highest Post-Baseline value within the timeframe of post-baseline collection up to when patient discontinued (up to 59 weeks)
Reported as:
Number · participants
Fasting Glucose, Highest Post-Baseline Value
participantsR1507_Baseline Glucose NormalR1507_Baseline Impaired Fasting GlucoseR1507_Baseline Diabetes MellitusR1507_Baseline Missing
Normal (< 140 mg/dL)21310
Impaired Fasting Glucose (≥ 140 to ≤ 200 mg/dL)2110
Diabetes Mellitus (> 200 mg/dL)0000
Missing3002
SecondaryHemoglobin A1c (HbA1c)

Standard safety monitoring includes baseline Electrocardiogram (ECG), Fasting glucose and HbA1c, monthly urine pregnancy test in female patients of childbearing potential and Human anti-human antibody (HAHA) testing. Data will be represented in the Serious Adverse Event (SAE) Adverse Event (AE) section of Protocol Registration System (PRS).

Time frame:
screening

No measurements were reported for this outcome.

SecondaryMonthly Urine Pregnancy Test in Female Patients of Childbearing Potential

Standard safety monitoring includes baseline Electrocardiogram (ECG), Fasting glucose and HbA1c, monthly urine pregnancy test in female patients of childbearing potential and Human anti-human antibody (HAHA) testing. Not posted; it will be represented in the Serious Adverse Event (SAE) Adverse Event (AE) section of Protocol Registration System (PRS).

Time frame:
Within 7 days of starting treatment (baseline visit)

No measurements were reported for this outcome.

SecondaryNumber of Participants With Positive Results for Human Anti-human Antibody (HAHA) Testing

Number of participants who tested positive for Human anti-human antibody (HAHA) testing for immunogenicity. To determine HAHA specificity, screened positive samples were tested in a confirmatory assay in the presence of 10 ug/mL R1507. Samples with \> 19.7% inhibition were considered true positives, whereas those with \< 19.7% inhibition were considered to be false positives.

Time frame:
prior to dosing on week 1 (day 1), week 4 (day 22), week 10 (day 64), final visit, follow up visit and 12 weeks post last dose (up to 71 weeks)
Reported as:
Number · participants
Number of Participants With Positive Results for Human Anti-human Antibody (HAHA) Testing
participantsR1507
POSITIVE1
FALSE POSITIVE5
SecondaryElectrocardiogram (ECG)

12 lead ECG is required at baseline and will be measured during the trial as clinically indicated at the discretion of the investigators. For each reading, QTcF value will be calculated as the QT value (seconds) divided by the cube root of the RR interval in seconds (Fridericia correction). A listing will be generated showing, for each patient, the visits at which ECGs were taken and the results (normal or abnormal, as well as any comments provided).

Time frame:
baseline and thereafter as clinically indicated at the discretion of the investigator up to the time that the patient discontinued (up to 59 weeks)
Reported as:
Mean · ms (millisecond)
Electrocardiogram (ECG)
ms (millisecond)R1507
Summary of QTcF Interval (n = 2)421.5 ± 3.54
Change from Baseline (n = 1)24.0 ± NA
SecondaryPopulation Pharmacokinetics of R1507 and Tarceva

Population PK of R1507 and erlotinib were planned but not analyzed due to the termination of the trial.

Time frame:
Throughout study

No measurements were reported for this outcome.

SecondaryAssessment of Potential Predictive and Prognostic Biomarkers.

Total IGF-I, free IGF I/II and other potential biomarkers present in serum. Further putative biomarker analyses in blood and tumor samples were planned in the protocol for exploratory assessment of correlation with clinical outcome. None of these were analyzed due to the termination of the trial.

Time frame:
Throughout study

No measurements were reported for this outcome.

Adverse events

Collected over From start of treatment until 30 days after last dose (up to 64 weeks) or if the AE was related to study drug, up until the AE resolved. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
R1507—12/34 (35.3%)33/34 (97.1%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventR1507
ASTHENIAGeneral disorders1/34
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders1/34
MUCOSAL INFLAMMATIONGeneral disorders1/34
PAINGeneral disorders1/34
CONVULSIONNervous system disorders1/34
DISTURBANCE IN ATTENTIONNervous system disorders1/34
EPILEPSYNervous system disorders1/34
LUNG DISORDERRespiratory, thoracic and mediastinal disorders1/34
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders1/34
THROMBOTIC MICROANGIOPATHYBlood and lymphatic system disorders1/34
Most frequent other events
Showing 10 of 47
Most frequent other events
EventR1507
ASTHENIAGeneral disorders18/34
DECREASED APPETITEGeneral disorders15/34
DIARRHOEAGastrointestinal disorders15/34
COUGHRespiratory, thoracic and mediastinal disorders9/34
MUSCLE SPASMSMusculoskeletal and connective tissue disorders9/34
VOMITINGGastrointestinal disorders7/34
NAUSEAGastrointestinal disorders6/34
RASHSkin and subcutaneous tissue disorders6/34
NAIL TOXICITYSkin and subcutaneous tissue disorders5/34
SKIN TOXICITYSkin and subcutaneous tissue disorders5/34

Baseline characteristics

Age Continuous
Age Continuous(years)R1507
Mean59.9 ± 11.43
Sex: Female, Male
Sex: Female, Male(Participants)R1507
Female18
Male16
08

Study locations

16 sites
  • Santa Monica, California 90404, United States
  • Miami, Florida 33101, United States
  • Boston, Massachusetts 02114, United States
  • Boston, Massachusetts 02115, United States
  • Boston, Massachusetts 02215, United States
  • Hickory, North Carolina 28602, United States
  • Calgary, Alberta T2N 4N2, Canada
  • Ottawa, Ontario K1H 8L6, Canada
  • Montreal, Quebec H3A 1A1, Canada
  • Montreal, Quebec H3G 1A4, Canada
  • Marseille, 13015, France
  • Paris, 75230, France
  • Villejuif, 94805, France
  • Gdansk, 80-211, Poland
  • Lublin, 20-950, Poland
  • Poznan, 60-569, Poland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2008
First posted
Oct 16, 2008
Start
Nov 2008
Primary completionActual
Feb 2010
CompletionActual
Feb 2010
Results first posted
Sep 16, 2011
Last update
Jun 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00773383
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 16, 2008
Start date
Nov 2008
Primary completion
Feb 2010
Completion
Feb 2010
Results posted
Sep 16, 2011
Last update
Jun 24, 2013

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teprotumumab

Start the discussion